Standard BioTools Reports Strong Q3 2024 Performance
Company Announcements

Standard BioTools Reports Strong Q3 2024 Performance

Standard BioTools ( (LAB) ) has issued an announcement.

Standard BioTools Inc. reported a third-quarter 2024 revenue of $45 million, highlighting a 50% improvement in adjusted EBITDA and a 35% reduction in net loss year-over-year. The company operationalized $80 million in merger synergies, aiming for adjusted EBITDA break-even by 2026. With a strong balance sheet, they are focusing on commercial execution and investing in growth within their multi-omics portfolio, while also pursuing strategic mergers and acquisitions to solidify their position in the life science tools industry.

Learn more about LAB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyStandard BioTools reports Q3 EPS (7c), consensus (9c)
Carrie WilliamsStandard Biotools Inc (LAB) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App